REPL Insider Trading Activity and SEC Form 4 Filings
REPL insider trading summary
Over the past 12 months, insiders at Replimune Group, Inc. (REPL) reported 18 sales worth $2.3M by 7 insiders and no open-market purchases on SEC Form 4. Net insider selling was $2.3M.
Latest REPL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 2, 2026 | Kapil Dhingra | Director | Sell | $409K (21,500 @ $19.00) |
| Aug 17, 2026 | Emily Luisa Hill | Chief Financial Officer | Sell | $132K (9,256 @ $14.28) |
| Aug 10, 2026 | Andrew Schwendenman | Chief Accounting Officer | Sell | $99K (7,632 @ $12.97) |
| Aug 10, 2026 | Konstantinos Xynos | Chief Medical Officer | Sell | $148K (11,447 @ $12.97) |
| Aug 10, 2026 | Sushil Patel | Chief Executive Officer | Sell | $510K (39,341 @ $12.97) |
| Aug 10, 2026 | Emily Luisa Hill | Chief Financial Officer | Sell | $148K (11,448 @ $12.97) |
| Jun 1, 2026 | Christopher Sarchi | Chief Commercial Officer | Sell | $111K (12,000 @ $9.24) |
| May 18, 2026 | Konstantinos Xynos | Chief Medical Officer | Sell | $71K (14,023 @ $5.08) |
| May 18, 2026 | Philip Astley-Sparke | Director | Sell | $90K (17,657 @ $5.08) |
| May 18, 2026 | Andrew Schwendenman | Chief Accounting Officer | Sell | $40K (7,894 @ $5.08) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.